

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Witham Memorial Hospital 2. 2605 N Lebanon St. Lebanon, IN 46052		In accordance with letter dated December 7, 2020,	4. Expiration Date: June 30, 2024
		3. License No.: 13-23331-01 is amended in its entirety to read as follows:	5. Docket No.: 030-20926 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed	A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed	B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-23331-01

Docket or Reference No.:
030-20926

Amendment No. 27

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 2605 N Lebanon St., Lebanon, Indiana, 46052.

11. The Radiation Safety Officer (RSO) for this license is Steven A. Fritsch, M.D.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized UserMaterial and Use

Caryn Cockerill Anderson, M.D.

10 CFR 35.100 and 35.200

Anwar T. Ashraf, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Edward R. Bartley, M.D.

10 CFR 35.100 and 35.200

Richard L. Becker, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Eric E. Beltz, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Margaret Brengle, M.D.

10 CFR 35.100 and 35.200

Matthew R. Brown, M.D.

10 CFR 35.100, 35.200, and 35.300

Michael S. Conley, M.D.

10 CFR 35.100 and 35.200

Ryan Matthew Dhaemers, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Joshua D. Dowell, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

Jack M. Drew, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

Laura Dugan, M.D.

10 CFR 35.100 and 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-23331-01

Docket or Reference No.:
030-20926

Amendment No. 27

Authorized User

Martha Dwenger, M.D.

Eric D. Elliot, M.D.

Janalyn P. Ferguson, M.D.

William C. Fischer, M.D.

Vincent L. Flanders, M.D.

Steven A. Fritsch, M.D.

David R. Gulliver, M.D.

Thomas Hagman, M.D.

Richard L. Hallet, M.D.

Warren Kent Hansen, M.D.

Carolyn R. Herman, M.D.

Kelly K. Horst, M.D.

Jaimie M. Howell, M.D.

Anthony C. Illing, M.D.

Matthew M. Jones, M.D.

Theodore P. Labus, M.D.

Carlo Roberto Lazzaro, M.D.

Charles A. Lerner, M.D.

Matthew Locker, M.D.

John Mark Michael, M.D.

John A. Morton, M.D.

Jack J. Moss, M.D.

Material and Use

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100 and 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 13-23331-01

Docket or Reference No.:
030-20926

Amendment No. 27

Authorized User

Charles C. Mulry, M.D.

Anuj A. Patel, M.D.

J. Michael Phelps, Jr.

Frank J. Pistoia, M.D.

Ryan N. Sauer, M.D.

Cristina N. Shinaver, M.D.

Michael S. Skulski, M.D.

Larry L. Stover, M.D.

Marc P. Underhill, M.D.

Lori J. Wells, M.D.

Brian J. Wiegel, M.D.

Material and Use

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100 and 35.200

10 CFR 35.100, 35.200, and 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


License No.: 13-23331-01

Docket or Reference No.:
030-20926

Amendment No. 27

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated January 15, 2014 (ML14024A667)
- B. Letter dated February 16, 2016 (ML16062A419)
- C. Letter dated April 4, 2016 (ML16106A318)
- D. Letter dated May 4, 2016 (ML16138A346)
- E. Letter dated September 21, 2016 (ML16281A612)
- F. Letter dated August 10, 2016 (ML16336A445)
- G. Letter dated November 15, 2019 (ML19329D938)
- H. Letter dated January 20, 2020 (ML20030A056)
- I. Letter dated December 7, 2020 (ML20343A054)



FOR THE U. S. NUCLEAR REGULATORY COMMISSION

Date: March 3, 2021By: _____
Bryan A. Parker
Region III